

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**  
**華康生物醫學控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 8622)**

**APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Huakang Biomedical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, with effect from the date of this announcement, Mr. He Jiaming (“**Mr. He**”) has been appointed as an executive Director. Mr. He joined the Group as a business development director in January 2019, and is responsible for evaluating and developing new products in connection with male fertility and exploring overseas business cooperation opportunities.

Mr. He, aged 34, graduated from University of Manchester in the United Kingdom in 2010, with a combined bachelor and master degree in chemistry. Mr. He has over 4 years of experience in the fields of biochemistry and international trading prior to joining the Group.

In relation to his new appointment as an executive Director, Mr. He will enter a service contract with the Company for an initial fixed term of three years commencing from the date of appointment and could be terminated by either party giving not less than three-months’ notice. Mr. He shall hold office until the next following annual general meeting and shall then be eligible for re-election at that meeting and will be subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Mr. He will be entitled to a Director’s emolument of HKD520,000 per annum under the Director’s service contract (which is determined by the Board upon the recommendation of the remuneration committee of the Company with reference to Mr. He’s experiences, knowledge, qualification, duties and responsibilities within the Company and the prevailing market conditions), and such management bonus and other benefits as may be determined by and at the sole discretion of the Board (upon the recommendation of the remuneration committee) from time to time.

Save as disclosed above, as at the date of this announcement, Mr. He (i) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders (as defined in the Rules Governing the Listing of Securities on GEM of Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”)) of the Company or other members of the Company; (ii) does not have any interest or short positions in any shares, underlying shares or

debentures of the Company or any of its associated corporations as defined in Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iii) has not held any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Saved as disclosed above, Mr. He and the Company confirm that there is no further information to be disclosed pursuant to the Rules 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules in relation to his appointment nor are there other matters that need to be brought to the attention of the shareholders of the Company in connection with Mr. He's appointment as an executive Director.

The Board would like to take this opportunity to welcome Mr. He in joining the Board.

By order of the Board  
**Huakang Biomedical Holdings Company Limited**  
**Zhang Shuguang**  
*Chairman and Executive Director*

Hong Kong, 14 January 2020

*As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Yeung David Wai Chow, Mr. Kwok Chi Shing and Mr. Chan Kin Sang.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Company Announcements" page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least seven days from the date of publication and on the Company's website at [www.huakangbiomedical.com](http://www.huakangbiomedical.com).*